1. The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer
   Kathrine Bjersand et al, 2017, PLOS ONE CrossRef
2. Therapeutic potential of combination therapy of soluble VEGF receptor 1 and conventional chemotherapy for ovarian cancer growth
   Noriko Sato et al, 2020, Journal of Obstetrics and Gynaecology Research CrossRef
3. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis
   Amilcar Barreta et al, 2019, Human Pathology CrossRef
4. Quantitative analysis of the human ovarian carcinoma mitochondrial phosphoproteome
   Na Li et al, 2019, Aging CrossRef
5. The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer
   Meryem El Azzouzi et al, 2023, Diagnostics CrossRef
6. Zebrafish: A Model Organism to Understand Tumor Angiogenesis Mechanism
   Krishnasamy Naidu Gopal Hariprabu et al, 2022, Zebrafish Model for Biomedical Research CrossRef
7. The functional consequences and prognostic value of dosage sensitivity in ovarian cancer
   Zichuang Yan et al, 2017, Molecular BioSystems CrossRef
8. Ang-1 and VEGF: central regulators of angiogenesis
   Yuanqin Zhao et al, 2024, Molecular and Cellular Biochemistry CrossRef
9. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients
   Venus Dalal et al, 2018, Clinica Chimica Acta CrossRef
10. Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients
    Beata Kotowicz et al, 2017, PLOS ONE CrossRef
11. Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens
    Allison L. Hunt et al, 2021, iScience CrossRef
12. Two Biosensors for the Determination of VEGF-R2 in Plasma by Array SPRi
    Lukasz Oldak et al, 2022, Molecules CrossRef
13. Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGF‑R2 in patients with ovarian cancer at FIGO stages�I-II
    Ingiridur Skirnisdottir et al, 2018, International Journal of Oncology CrossRef
14. Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients
    Valéria Tavares et al, 2021, The Pharmacogenomics Journal CrossRef
15. Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine
    Cheng Zhang et al, 2018, Integrative Cancer Therapies CrossRef